WO2000029012A3 - Methods of alleviating cancer symptoms - Google Patents

Methods of alleviating cancer symptoms Download PDF

Info

Publication number
WO2000029012A3
WO2000029012A3 PCT/US1999/026636 US9926636W WO0029012A3 WO 2000029012 A3 WO2000029012 A3 WO 2000029012A3 US 9926636 W US9926636 W US 9926636W WO 0029012 A3 WO0029012 A3 WO 0029012A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer symptoms
alleviating cancer
alleviating
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/026636
Other languages
French (fr)
Other versions
WO2000029012A8 (en
WO2000029012A2 (en
Inventor
Kuber T Sampath
Charles M Cohen
David C Rueger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creative Biomolecules Inc
Original Assignee
Creative Biomolecules Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22704676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000029012(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE69920033T priority Critical patent/DE69920033T3/en
Priority to JP2000582058A priority patent/JP4892131B2/en
Priority to EP99958892A priority patent/EP1131087B2/en
Priority to AU16167/00A priority patent/AU1616700A/en
Priority to DK99958892T priority patent/DK1131087T4/en
Application filed by Creative Biomolecules Inc filed Critical Creative Biomolecules Inc
Priority to AT99958892T priority patent/ATE275416T1/en
Priority to CA2349038A priority patent/CA2349038C/en
Publication of WO2000029012A2 publication Critical patent/WO2000029012A2/en
Publication of WO2000029012A3 publication Critical patent/WO2000029012A3/en
Publication of WO2000029012A8 publication Critical patent/WO2000029012A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The invention provides methods for alleviating the symptoms of cancer by administering a morphogen. The present invention also provides compositions and methods for the inhibition or prevention of unchecked growth of cancer cells or stimulate differentiation of cancer cells.
PCT/US1999/026636 1998-11-13 1999-11-12 Methods of alleviating cancer symptoms Ceased WO2000029012A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2349038A CA2349038C (en) 1998-11-13 1999-11-12 Methods of alleviating cancer symptoms
JP2000582058A JP4892131B2 (en) 1998-11-13 1999-11-12 How to relieve cancer symptoms
EP99958892A EP1131087B2 (en) 1998-11-13 1999-11-12 Alleviatation of prostate cancer symptoms
AU16167/00A AU1616700A (en) 1998-11-13 1999-11-12 Methods of alleviating cancer symptoms
DK99958892T DK1131087T4 (en) 1998-11-13 1999-11-12 Relief of prostate cancer symptoms
DE69920033T DE69920033T3 (en) 1998-11-13 1999-11-12 Reduction of prostate cancer symptoms
AT99958892T ATE275416T1 (en) 1998-11-13 1999-11-12 METHOD FOR REDUCING CANCER SYMPTOMS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19123998A 1998-11-13 1998-11-13
US09/191,239 1998-11-13

Publications (3)

Publication Number Publication Date
WO2000029012A2 WO2000029012A2 (en) 2000-05-25
WO2000029012A3 true WO2000029012A3 (en) 2000-11-16
WO2000029012A8 WO2000029012A8 (en) 2001-01-11

Family

ID=22704676

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/026636 Ceased WO2000029012A2 (en) 1998-11-13 1999-11-12 Methods of alleviating cancer symptoms

Country Status (10)

Country Link
EP (2) EP1435243A3 (en)
JP (2) JP4892131B2 (en)
AT (1) ATE275416T1 (en)
AU (1) AU1616700A (en)
CA (1) CA2349038C (en)
DE (1) DE69920033T3 (en)
DK (1) DK1131087T4 (en)
ES (1) ES2226467T5 (en)
PT (1) PT1131087E (en)
WO (1) WO2000029012A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026713A1 (en) * 2000-05-30 2001-12-06 Walter Sebald Mutein a chain of a protein from the superfamily of the growth factor TGF-beta
NZ573739A (en) * 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly colorectal tumor - TAT201
CA2561809A1 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
US20100035240A1 (en) * 2004-08-10 2010-02-11 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
EP1802326A2 (en) * 2004-09-09 2007-07-04 Stryker Corporation Methods for treating bone tumors using bone morphogenic proteins
JP2008169116A (en) * 2005-04-18 2008-07-24 Tokyo Medical & Dental Univ Anti-hepatitis C virus agent containing BMP-7
WO2006125867A1 (en) 2005-05-27 2006-11-30 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic protein 4 and osteogenic devices and pharmaceutical products containing thereof
ES2642591T3 (en) 2005-05-27 2017-11-16 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic protein 3 and osteogenic devices and pharmaceutical products containing the same
US7910552B2 (en) 2005-05-27 2011-03-22 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof
DK3117833T3 (en) * 2005-07-19 2019-03-18 Stemgen S P A Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF
GB0615129D0 (en) * 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739107A (en) * 1991-03-11 1998-04-14 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
WO1998050061A1 (en) * 1997-05-07 1998-11-12 Biogen, Inc. Novel therapies for cystic kidney disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652118A (en) † 1991-03-11 1997-07-29 Creative Biomolecules, Inc. Nucleic acid encoding a novel morphogenic protein, OP-3
DK0575555T3 (en) † 1991-03-11 2001-11-05 Curis Inc Protein-induced morphogenesis
US6287816B1 (en) * 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
AU681594B2 (en) † 1992-07-31 1997-09-04 Stryker Corporation Morphogen-induced nerve regeneration and repair
EP0680334B1 (en) * 1992-09-15 2000-12-13 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
EP0756628B1 (en) † 1994-04-29 2007-11-14 Curis, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
JPH08225454A (en) * 1995-02-23 1996-09-03 Chugai Pharmaceut Co Ltd Microsphere formulation
FR2737501B1 (en) * 1995-07-31 1997-10-24 Transgene Sa NOVEL AUXILIARY VIRUSES FOR THE PREPARATION OF RECOMBINANT VIRAL VECTORS
US6379961B1 (en) † 1995-09-21 2002-04-30 The Trustees Of Columbia University In The City Of New York Uses of bone morphogenetic proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739107A (en) * 1991-03-11 1998-04-14 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
WO1998050061A1 (en) * 1997-05-07 1998-11-12 Biogen, Inc. Novel therapies for cystic kidney disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREWS PETER W ET AL: "Inhibition of proliferation and induction of differentiation of pluripotent human embryonal carcinoma cells by osteogenic protein-1 (or bone morphogenetic protein-7).", LABORATORY INVESTIGATION, vol. 71, no. 2, 1994, pages 243 - 251, XP000929102, ISSN: 0023-6837 *
SODA HIROSHI ET AL: "Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units.", ANTI-CANCER DRUGS, vol. 9, no. 4, April 1998 (1998-04-01), pages 327 - 331, XP000915431, ISSN: 0959-4973 *

Also Published As

Publication number Publication date
DK1131087T3 (en) 2004-12-13
WO2000029012A8 (en) 2001-01-11
ES2226467T5 (en) 2009-08-27
AU1616700A (en) 2000-06-05
ATE275416T1 (en) 2004-09-15
ES2226467T3 (en) 2005-03-16
JP4892131B2 (en) 2012-03-07
JP2002529513A (en) 2002-09-10
EP1435243A2 (en) 2004-07-07
WO2000029012A2 (en) 2000-05-25
DE69920033D1 (en) 2004-10-14
CA2349038C (en) 2011-08-02
CA2349038A1 (en) 2000-05-25
PT1131087E (en) 2004-12-31
DE69920033T3 (en) 2009-10-08
DK1131087T4 (en) 2009-08-03
EP1131087B1 (en) 2004-09-08
JP2010150278A (en) 2010-07-08
EP1435243A3 (en) 2005-02-09
DE69920033T2 (en) 2005-09-22
EP1131087A2 (en) 2001-09-12
EP1131087B2 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
AU2212299A (en) Compositions and methods for the treatment of tumor
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
AU2495200A (en) Compositions and methods for the treatment of tumor
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
ZA200110504B (en) Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria.
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
IL143921A0 (en) Compositions for the treatment and prevention of tumors and tumor-related disorders
BG104698A (en) Glucocorticoid-selective anti-inflammatory agents
AU1774097A (en) Pharmaceutical compositions for the treatment of rhinitis
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
WO2000029012A8 (en) Methods of alleviating cancer symptoms
AU7671198A (en) Methods for the inhibition of neuronal activity by local delivery of adenosi ne
AU1044500A (en) Imidazonaphthyridines
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU7520898A (en) Tetrahydropyrido compounds
AU6019700A (en) Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
GB9907571D0 (en) Compounds
AU2021601A (en) Composition for the treatment of dandruff
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
WO2002020000A3 (en) Combined estrogen blockade of the breast with exemestane and raloxifene
AU2001264522A1 (en) Methods and compositions for the prevention of myopia

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 16167

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 582058

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2349038

Country of ref document: CA

Ref country code: CA

Ref document number: 2349038

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999958892

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999958892

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999958892

Country of ref document: EP